Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992605 | 0.83 | DAO (0.65) | DAOKDM4ERAB9AGAAMAPT | |
| SCHEMBL6954479 | 0.81 | ALDH1A1 (0.56) | DAOKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL6625289 | 0.77 | ALDH1A1 (0.52) | KDM4ERAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL8223574 | 0.77 | DAO (0.61) | DAOALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL1161150 | 0.77 | DAO (0.58) | DAOKDM4ERAB9AALDH1A1HPGD | |
| SCHEMBL1244615 | 0.75 | DAO (1.00) | DAOKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1244092 | 0.75 | ALDH1A1 (0.50) | KDM4ERAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1244777 | 0.75 | ALOX15 (0.55) | KDM4ERAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1244790 | 0.75 | RAB9A (0.50) | KDM4ERAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2333687 | 0.74 | DAO (0.71) | DAOKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626860-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | ReWind Therapeutics NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025026270-A1 | BENZO NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-02-06 | — | — | WO | disclosed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| EP-3668877-B1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2024-05-01 | — | — | EP | disclosed |
| EP-3189059-B1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2023-02-22 | — | — | EP | disclosed |
| EP-3189059-B1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2023-02-22 | — | — | EP | disclosed |
| CN-112574230-B | Peptidyl arginine deiminase inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-110194770-B | Peptidyl arginine deiminase inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-109641918-B | Imidazoles as inhibitors of histone demethylases | 欧洲肿瘤研究所有限责任公司 | 2021-12-21 | — | — | CN | disclosed |
| US-10980777-B2 | Indole derivatives as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-04-20 | — | — | US | disclosed |
| US-20040048878-A1 | Cyclopentathienopyrroles and cyclopentafuranopyrroles for treating disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis. | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-11 | — | — | US | disclosed |
| EP-1391460-A1 | Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1088824-B1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030195361-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PFIZER INC. | 2003-10-16 | — | — | US | disclosed |
| US-6576653-B2 | For therapy of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis | PFIZER INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | DU BOIS DAISY JOE (US) | 2002-12-05 | — | — | US | disclosed |
| US-6399601-B1 | ANTIDIABETIC AGENTS; NERVOUS SYSTEM DISORDERS; ANTICHOLESTEROL AGENTS | PFIZER INC. | 2002-06-04 | — | — | US | disclosed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980777-B2 | Indole derivatives as histone demethylase inhibitors | KDM1B, KDM1A, INMT | DAO 1393/4885KDM4E 24/4885RAB9A 3283/4885 |
| US-20030195361-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, GYS1, PYGM | DAO 1915/4885KDM4E 3388/4885RAB9A 3214/4885 |
| US-20040048878-A1 | Cyclopentathienopyrroles and cyclopentafuranopyrroles for treating disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis. | HRH4, HRH2, HRH1 | DAO 2815/4885KDM4E 1848/4885RAB9A 2437/4885 |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, PYGM, PYGB | DAO 1906/4885KDM4E 2517/4885RAB9A 4025/4885 |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | DAO 774/4885KDM4E 2087/4885RAB9A 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.